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Summary. Background: Histidine-rich glycoprotein (HRG)
regulates coagulation through its ability to bind and neu-
tralize heparins. HRG associates with Zn2+ to stimulate
HRG–heparin complex formation. Under normal condi-
tions, the majority of plasma Zn2+ associates with human
serum albumin (HSA). However, free fatty acids (FFAs)
allosterically disrupt Zn2+ binding to HSA. Thus, high
levels of circulating FFAs, as are associated with diabetes,
obesity, and cancer, may increase the proportion of
plasma Zn2+ associated with HRG, contributing to an
increased risk of thrombotic disease. Objectives: To char-
acterize Zn2+ binding by HRG, examine the influence
that FFAs have on Zn2+ binding by HSA, and establish
whether FFA-mediated displacement of Zn2+ from HSA
may influence HRG–heparin complex formation. Meth-
ods: Zn2+ binding to HRG and to HSA in the presence
of different FFA (myristate) concentrations were exam-
ined by isothermal titration calorimetry (ITC) and the
formation of HRG–heparin complexes in the presence of
different Zn2+ concentrations by both ITC and ELISA.
Results and conclusions: We found that HRG possesses 10
Zn2+ sites (K0 = 1.63 9 105) and that cumulative binding
of FFA to HSA perturbed its ability to bind Zn2+. Also
Zn2+ binding was shown to increase the affinity with
which HRG interacts with unfractionated heparins, but
had no effect on its interaction with low molecular weight
heparin (~ 6850 Da). [Correction added on 1 December
2014, after first online publication: In the preceding
sentence, “6850 kDa” was corrected to “6850 Da”.]
Speciation modeling of plasma Zn2+ based on the data
obtained suggests that FFA-mediated displacement of
Zn2+ from serum albumin would be likely to contribute
to the development of thrombotic complications in indi-
viduals with high plasma FFA levels.
Keywords: fatty acids; heparin; histidine-rich glycoprotein;
plasma albumin; zinc.
Introduction
Histidine-rich glycoprotein (HRG) is a plasma adaptor
protein present at a concentration of 1.3–2.0 lM in adult
blood [1,2]. HRG natively exists as a dimer, forming
multiprotein complexes that regulate coagulation and
other biological processes, including immune complex
clearance, cell proliferation, cell adhesion, and angiogene-
sis [1]. This has led to its description as ‘the Swiss army
knife of mammalian plasma’ [3]. High levels of HRG are
associated with the clinical presentation of cardiovascular
disorders, including blood vessel occlusion and thrombo-
philia [4–6]. HRG thus seems to play a particularly
important role in regulating blood clotting. The primary
structure of HRG contains two cystatin-like domains at
the N-terminus, a histidine-rich region (HRR) flanked by
two proline-rich regions, and a C-terminal domain [7,8].
The distinctive HRR is composed of repeating GHHPH
motifs [1]. This domain associates with Zn2+ to alter the
binding characteristics of the protein, such that the affin-
ity of HRG for a number of molecules, including the
natural anticoagulants heparin and heparan sulfate, is
increased [9]. This, in turn, enables neutralization of these
anticoagulants, leading to a prothrombotic effect via
inhibition of antithrombin III activity [10,11]. Thus,
Zn2+ binding by HRG provides a potential means of
regulating its function. An anticoagulatory role for
Zn2+–HRG has also been suggested, as Zn2+ can poten-
tiate the binding of HRG to factor XIIa [12], but this is
less clear.
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Indeed, plasma Zn2+ has emerged as an important reg-
ulator of hemostasis and thrombosis [13]. Zinc deficiency
is associated with defects in platelet aggregation and
increased bleeding times, effects that can be reversed with
zinc supplementation [14–17]. Plasma Zn2+ levels are
highly regulated, and under normal conditions ~ 75% of
the total 20 lM plasma Zn2+ (~ 15 lM) is bound to
serum albumin [18], and not to HRG [19]. Much of the
remaining 5–6 lM Zn2+ in plasma is strongly bound to
other proteins (such as a2-macroglobulin), with the con-
centration of free/exchangeable (weakly bound) Zn2+ in
plasma thought to be in the nanomolar range [20,21]. It
is thought that Zn2+ release from platelet-derived a-gran-
ules may provide enough Zn2+ locally to modify
HRG–heparin interactions and aid in the initiation of
coagulation [11,22]. Mahdi et al. [23] reported that the
free Zn2+ concentration close to activated platelets is 7–
10 lM, and may be even higher in the growing thrombus.
Despite this, the Zn2+-binding properties of HRG and
the role that Zn2+ plays in influencing HRG–heparin
interactions are not fully understood.
Previously, we identified the primary Zn2+-binding site
on serum albumin (often referred to as site A), which
consists of N-ligands from His67 and His247 and
O-ligands from Asn99, Asp249, and H2O [24,25]. Serum
albumin transports fatty acids in the circulation, and binds
non-esterified fatty acids [termed free fatty acids [FFAs])
of various chain lengths, ranging from C10 to C24, at five
high-affinity sites (termed FA1–FA5) and several lower-
affinity sites [26–28]. Fatty acid binding at site FA2
induces a conformational switch that disengages the Zn2+-
binding residues in domain II relative to those in domain I
[24,29], as shown in Fig. 1. Under normal physiologic
conditions, the plasma concentration of FFAs is ~ 250–
500 lM at rest [30]. This represents < 1 mole equivalent
(mol eq.) relative to the plasma concentration of serum
albumin. However, FFA levels are dynamic and, for
instance, rise following meals and during periods of exer-
cise. Crucially, elevated FFA levels are also associated with
a range of disorders, including obesity [31,32], diabetes
[33], fatty liver disease [34], and cancer [35]. For example,
in obese individuals, plasma concentrations of FFA (at
rest) are often two to three times higher [32], and in some
cancer patients they are four to six times higher, than in
controls [36]. Such disorders are associated with an
increased risk of thrombotic complications [37,38]. For
example, thromboembolism (caused by obstructive blood
clots) is the second leading cause of death associated with
malignancy [37]. Collectively, these observations led us to
hypothesize that, under conditions where FFA levels are
elevated, Zn2+ displaced from serum albumin could bind
HRG to enhance its interaction with heparin/heparan
sulfate and induce a procoagulatory effect [39].
With this in mind, we sought to gain a fuller under-
standing of the Zn2+-binding properties of HRG and the
role of Zn2+ in controlling HRG–heparin interactions by
using isothermal titration calorimetry (ITC) and an
ELISA-based method. Furthermore, we used ITC to
examine whether plasma FFA levels may regulate the
Zn2+-dependent HRG–heparin interactions (via Zn2+
displacement from serum albumin) to probe the interac-
tive binding of myristate (Myr) and Zn2+ to serum albu-
min. Myr was used because it balances solubility issues
with an ability to still bind to serum albumin in a manner
that closely matches that of the more physiologically rele-
vant palmitate (C16) and stearate (C18) [26], albeit with
slightly weaker affinity [40]. Zn2+-speciation modeling
based on the resultant data suggests that the maintenance
of FFA levels and/or free/exchangeable plasma Zn2+ lev-
els would probably provide new avenues for therapeutic
intervention in managing thrombotic complications in
high-risk individuals.
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Fig. 1. The fatty acid/Zn2+ switch on serum albumin. (A) Overlay
of crystal structures of human serum albumin with (gray; Protein
Data Bank [PDB] 1BJ5 [26]) and without (green; PDB 1AO6 [61])
myristate (Myr) bound, showing the location of the major Zn2+-
binding site. (B) Close-up showing the movement of Zn2+-coordinat-
ing residues His247 and Asp249 relative to His67 and Asn99 between
the two structures.
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Materials and methods
Purification of human and rabbit HRG
HRG was purified directly from either human plasma
(TCS Biosciences, Buckingham, UK) or, for experiments
detailed in the Supporting information, rabbit serum
(Sigma-Aldrich, Poole, UK) with immobilized metal affin-
ity chromatography. Plasma or serum was centrifuged
(4000 9 g, 30 min) and filtered through a 0.45-lm syringe
filter (Sartorius, Epsom, UK), and imidazole was added
(5 mM final) together with the equilibration buffer
(10 mM Tris, 150 mM NaCl, 5 mM imidazole, pH 8). A 5-
mL HisTrap nickel column (GE Healthcare Life Sciences,
Little Chalfont, UK) was equilibrated with 5–10 column
volumes of the equilibration buffer, and sample (50 mL)
was loaded. The column was washed with equilibration
buffer and then with a 70 : 30 mixture of equilibration/
elution buffer (10 mM Tris, 150 mM NaCl, 400 mM imid-
azole, pH 8). HRG was eluted with elution buffer. The
purified HRG sample was then dialyzed to remove any
bound metals in the buffer of choice for further experi-
ments, or in 50 mM ammonium carbonate prior to lyoph-
ilization.
ITC
ITC experiments were carried out with a MicroCal VP-
ITC instrument (GE Healthcare Life Sciences) in 50 mM
Tris and 140 mM NaCl (pH 7.4) at 25 °C. Titrants (ZnCl2
and heparins) were added to the reaction buffer, and the
pH was adjusted to 7.4 to match the buffer in the ITC
cell containing the protein. Solutions were degassed at
22 °C for 15 min prior to performance of the experiment.
Typical titrations performed were one 2-lL injection over
4 s followed by up to 55 injections of 5 lL over 10 s with
an adequate interval of 240 s between injections to allow
complete equilibration. The stirring speed was 307 r.p.m.
Heats of dilution were accounted for with blank titrations
performed by injecting ligand solution into reaction buf-
fer and subtracting the averaged heat of dilution from the
main experiments. Alternatively, in cases of saturated
binding, blank titrations were omitted where the averaged
residual signal of the last injections was used to determine
the heat of dilution. Raw data were processed with MICRO-
CAL ORIGIN software, and data were fitted by use of the
same software; the results presented are representative of
multiple experiments. In all cases, the errors stated repre-
sent the fitting errors from individual experiments.
For fitting of the human serum albumin (HSA)–Zn2+
titration data in the presence and absence of Myr, initial
values for K1ITC and DH1 for the high-affinity site A
were determined with a sequential binding site model.
Subsequent fits to determine site A occupancy used a
‘two sets of sites’ model, with K1ITC and DH1 fixed, and
N1 varied. Simultaneous variation of N2, K2 and DH2
yielded good fits, but physically unreasonable data for the
latter values (but still resulted in a decrease in site A
occupancy). Hence, fits with either K2 and DH2 fixed at
values derived from fitting the data in the absence of
Myr, or fits with N2 fixed at either 1 or 2, were explored
(Tables S1 and S2). The resulting values for N1 from the
various fits were averaged.
ELISA
An ELISA experimental set-up was devised to investigate
the interaction between HRG and heparin compounds.
Unfractionated porcine plasma heparin (Acros Organics,
Loughborough, UK) or low molecular weight heparin
(LMWH) (6850 Da; Iduron, Manchester, UK) were
coated overnight at room temperature onto a heparin-
binding plate (Iduron) at a concentration of 25 lg mL1
in 50 mm HEPES, 150 mM NaCl and 0.2% Tween-20 at
pH 7.4. The wells were washed with the same buffer,
and then blocked with the same buffer supplemented
with 0.2% gelatin from fish skin (Sigma-Aldrich) for 1 h
at 37 °C. Human HRG was then incubated for 2 h over
a range of concentrations (0–3 lM) at 37 °C with or
without ZnCl2. The reaction was detected with primary
rabbit anti-HRG (Sigma-Aldrich) followed by alkaline
phosphatase-linked anti-rabbit antibody (Sigma-Aldrich),
and observed with p-nitrophenol phosphate substrate
(Sigma-Aldrich) at 405 nm.
Speciation modeling
The ‘Species’ module of the IUPAC Stability Constants
Database (version 5.6) was employed for speciation mod-
eling, with the conditional stability constants for HRG
and HSA determined in this work, and typical physio-
logic concentrations for exchangeable Zn2+ (15 lM),
HSA (620 lM), and HRG (1 or 2 lM). For the last of
these, the binding site concentration was assumed to be
10 times that of HRG, according to the stoichiometry
determined at high ionic strength. Averages and errors
were calculated by employing various combinations of
values for N1, N2 and K2 for HSA corresponding to the
fitting values (Tables S1 and S2), and two different con-
centrations for HRG (Table S3).
Results and discussion
We used ITC to examine the Zn2+-binding properties of
human HRG purified from blood plasma. Zn2+ binding
to human HRG was exothermic, and data analysis
revealed that human HRG is capable of binding
10 mol eq. (N = 10.3) of Zn2+ at near-physiologic ionic
strength (50 mM Tris, 140 mM NaCl, pH 7.4) with an
average apparent affinity, KITC, of
(8.06  0.40) 9 104 M1 (Fig. 2). Rabbit HRG has been
frequently used in biochemical studies, owing to its higher
© 2014 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
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abundance in rabbit plasma (~ 0.9 mg mL1) [41], but it
possesses a longer HRR (Fig. S1). Examination of Zn2+
binding to serum-purified rabbit HRG with the same
method and conditions revealed that the rabbit protein
bound 10 mol eq. (N = 10.4) of Zn2+, similarly to the
human HRG–Zn2+ interaction and in keeping with
previously reported data [41], but with a lower average
affinity than human HRG, with a KITC of
(4.39  0.33) 9 104 M1 (Fig. S2).
The influence of Zn2+ on the heparin-binding proper-
ties of human HRG was probed with ITC. Unfractionat-
ed porcine plasma heparin (molecular mass range of 3–
30 kDa) was titrated into samples of human HRG con-
taining different concentrations of ZnCl2 (Fig. 3). The
presence of Zn2+ had a marked effect on the mechanism
by which human HRG bound heparin. In the absence of
Zn2+, the interaction between heparin and HRG for the
first few injections gave rise to a less endothermic (or exo-
thermic) component of the isotherm. This initial form of
heparin binding was more pronounced in the presence of
5 lM Zn2+. This reveals that heparin binds HRG via dif-
ferent ‘modes’, whereby the less endothermic or exother-
mic mode of binding occurs with higher affinity than the
more endothermic, lower-affinity mode, and is modulated
by Zn2+. The possibility that the isotherm reflects both
Zn2+–heparin and heparin–HRG interactions was ruled
out because the Zn2+ concentration was identical in both
protein-containing and injectant solutions. It was possible
to fit curves to the endothermic data collected in the
absence and presence of 1 lM Zn2+, but not to the iso-
therm observed at 5 lM. The resultant curves suggest that
the second, endothermic mode most probably corresponds
to a single heparin site (N < 0.4 in each case). The calculated
KITC values for this mode were (2.44  0.25) 9 106 M1
with no Zn2+ and (2.44  0.54) 9 106 M1 in the presence
of 1 lM Zn2+, indicating that there is no Zn2+ dependence
for this mode of binding. It is important to note, however,
that the ‘real’ affinities are probably higher, as this analysis
does not take into account binding via the first mode. It was
also observed that there was a difference in the stoichiome-
try of heparin binding to HRG in the presence of 1 lM Zn2+
(as illustrated by a shift in the curve to the left) as compared
with the data without Zn2+ or with 5 lM Zn2+. This corre-
lates with a previous study revealing that complexes of 1 : 1
and 2 : 1 (HRG/heparin) can form, with formation of the
2 : 1 complex being enhanced by the presence of Zn2+ [42].
As unfractionated heparin was used in this instance, it was
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Fig. 2. Isothermal titration calorimetry data for Zn2+ binding to
human histidine-rich glycoprotein (HRG). Here, 55 injections of
5 lL of 150 lM ZnCl2 were delivered to samples of 10 lM HRG in
buffer containing 50 mM Tris and 140 mM NaCl (pH 7.4) over a per-
iod of 10 s with an adequate interval (240 s) between injections to
allow complete equilibration. The total Zn2+ concentration at the
end of the experiment was 24.6 lM. Raw data are shown in Fig. S5.
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Fig. 3. Isothermal titration calorimetry data showing the effect of
Zn2+ on heparin binding to human histidine-rich glycoprotein
(HRG). In the absence of Zn2+, the interaction between heparin and
HRG for the first few injections gives rise to a less endothermic (or
exothermic) component of the isotherm corresponding to a different
overlapping mode of binding, which is increasingly pronounced in
the presence of Zn2+. Here, 45 injections of 5 lL of 50 lM heparin
(average molecular mass assumed to be 15 kDa) were delivered to
samples of HRG (10 lM in buffer containing 50 mM Tris, 50 mM
NaCl and 0 lM [■], 1 lM [○] and 5 lM [▲] ZnCl2, pH 7.4) over a
period of 10 s with an adequate interval (240 s) between injections.
Zn2+ was included in the buffer at concentrations of 0, 1 and 5 lM.
Raw data are shown in Figs. S6–S8.
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not possible to assign an accurate molecular mass to the
titrant solution (an average mass of 15 kDa was used), and
so the x-axis in Fig. 3 is, to a large degree, arbitrary.
However, if we use the molar ratio of 0.4 observed in these
experiments to represent the 1 : 1 complex (which is the cal-
culated N-value for both the Zn2+-free and 5 lM Zn2+
datasets), then the molar ratio of 0.2 (which is the calculated
N-value for the 1 lM Zn2+ dataset) can be taken to repre-
sent the 2 : 1 complex. The data here suggest that higher
concentrations of Zn2+ (5 lM) inhibit formation of the 2 : 1
complex. The complexity of the interaction is a corollary of
the molecules involved, as HRG is probably able to bind
heparin at different regions, and heparin molecules them-
selves are heterogeneous (existing in varying chain lengths),
and, in the presence of Zn2+, interact differently with HRG,
depending on length.
As it was problematic to obtain quantitative informa-
tion from the ITC data, owing to the mix of interactions
giving rise to the different enthalpies observed, an ELISA
protocol was established to calculate the affinities
involved in this interaction. Unfractionated (3–30 kDa)
and fractionated LMWH (6850 Da) were used separately
in these studies. In each case, HRG bound heparin in a
concentration-specific manner (Fig. 4A,B). In the absence
of Zn2+, the average apparent Kd
0 value was 32.9 nM
(corresponding to K0 = 3.04 9 107 M1). This is consider-
ably stronger than the affinity derived from the ITC data
(KITC = 2.44 9 10
6
M
1), and probably reflects the Zn2+-
dependent mode of binding that could not be quantified
by ITC. The affinity of HRG for the unfractionated hep-
arin was even higher in the presence of 1 lM Zn2+ (aver-
age apparent Kd
0
= 5.1 nM). The stochiometry of binding
was similar in both cases, suggesting that the two binding
modes observed in the ITC experiments are mutually
exclusive (i.e. coordination of Zn2+ does not create addi-
tional heparin-binding sites). These data suggest that even
relatively small changes in plasma Zn2+ speciation are
likely to affect the heparin-binding properties of HRG
and its hemostatic functions. Zn2+ did not influence the
ability of HRG to bind LMWH; average Kd values were
~ 30 nM in both the presence and absence of 1 lM Zn2+
(Fig. 4B). Antithrombin has a high affinity for heparin,
with a Kd in the region of 10–20 nM [43], and was
reported to bind a fraction of heparin (termed low-affinity
heparin) with a Kd of 19 lM [44]. Taking these numbers
into account with the data obtained here, it is apparent
that HRG is a stronger competitor for heparin in the
presence of Zn2+.
Previous studies have indicated that the N1/N2 region
and the HRRs of HRG interact with heparin, and that
binding to the HRR is Zn2+-dependent [11,45]. From the
data presented, it would appear that HRG binds heparins
of essentially all chain lengths via its N1/N2 domain in a
Zn2+-independent manner, forming a 1 : 1 complex.
When larger heparin chains are present, binding affinity
for HRG is enhanced by Zn2+. In addition, the data sug-
gest that addition of 1 lM Zn2+ allows formation of 2 : 1
(HRG/heparin) complexes. This effect has previously
been shown only to occur with heparins of ≥ 10 kDa [42].
Longer-chain heparins presumably offer greater potential
for simultaneous binding of multiple HRG molecules to a
single chain. However, this is stated with caution, as the
data here do not fully reveal the binding mechanism. It is
also unclear why addition of 5 lM Zn2+ averted forma-
tion of 2 : 1 complexes, but it is likely that a higher pro-
portion of Zn2+ bound at the HRR would enhance
heparin binding at this site, which would increase the
number of heparin molecules bound per HRG molecule.
The data presented are significant, as heparins are used
clinically as anticoagulants, although there are some com-
plications with their use (particularly for unfractionated
heparin). Unfractionated heparin is plagued by a narrow
therapeutic window and an unpredictable dose–response
profile, as well as other problems, including the inability
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Fig. 4. Analysis of histidine-rich glycoprotein (HRG)-heparin bind-
ing using an ELISA-based assay. Influence of Zn2+ on binding of
human HRG to (A) unfractionated heparin (3–30 kDa) and (B) low
molecular weight heparin (6850 Da). Heparin (25 lg mL1) was
coated overnight onto a heparin-binding plate in 50 mm HEPES,
150 mM NaCl, and 0.2% Tween-20 (pH 7.4). The plate was then
washed with the same buffer, and then blocked with the same buffer
containing 0.2% gelatin. Human HRG was then added over a range
of concentrations (0–3 lM) with either 0 lM (■) or 1 lM (○) ZnCl2 in
triplicate, and incubated for 2 h. Detection was performed with pri-
mary rabbit anti-HRG followed by alkaline phosphatase-linked anti-
rabbit antibody, and observed with a p-nitrophenol phosphate sub-
strate at 405 nM.
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to promote inhibition of fibrin-bound thrombin and
platelet-bound factor Xa and the potential to trigger hep-
arin-induced thrombocytopenia. LMWHs have a more
predictable dose–response profile, but are still unable to
inhibit fibrin-bound thrombin and platelet-bound factor
Xa [46,47]. The observation that Zn2+ increases the affin-
ity of HRG for unfractionated heparin (which contains
heparins up to 30 kDa) and not LMWH may help to
explain the clinical differences observed between the for-
mer and the latter.
Recently, we examined the binding of Myr (C14) to
bovine serum albumin (BSA) by using ITC. This
revealed that even the presence of 1 mol eq. of Myr
perturbed albumin’s ability to bind Zn2+, and that
4 mol eq. of Myr was sufficient to almost completely
suppress Zn2+ binding [29]. To examine the effect of
FFAs on the Zn2+-binding properties of HSA, ITC
was performed with HSA (50 lM), loaded with increas-
ing molar equivalents of Myr (0–250 lM, corresponding
to 0–5 mol eq.) prior to titration with ZnCl2 (1.5 mM).
The resulting isotherms are shown in Fig. 5 (the full
dataset is shown in Fig. S3), where trends for decreas-
ing stoichiometry and a lowering of the overall affinity
of HSA for Zn2+ are observed. Two classes of binding
site were discernible for FFA-free HSA, yielding
K1ITC = 1.35 9 10
5
M
1 and K2ITC = 2.86 9 10
3
M
1.
The weaker-affinity binding site class corresponds to at
least one further metal-binding site with non-negligible
affinity for Zn2+; the existence of such secondary sites
is well documented in the literature [48–51]. All fits
shown in Fig. 5 correspond to a two-sets-of-sites model
with K1ITC, the binding constant for the highest-affinity
site (site A), now fixed at 1.35 9 105 M1, and the stoi-
chiometric factor N1 being varied. Various fitting
approaches were explored (Tables S1 and S2), and,
under all scenarios, the stoichiometric factor N1 for
site A decreased progressively, from 0.98 to 0.86 in the
absence of Myr, to 0.01–0.13 in the presence of
5 mol eq. of Myr (Fig. 6A). From these data, it is clear
that the high-affinity Zn2+ site had all but disappeared
at 5 mol eq. of Myr, although some weak Zn2+-binding
capacity (K2ITC < 10
4
M
1) from the secondary site(s)
remained (Table S1). In contrast to what was observed
for BSA [29], the secondary binding sites on HSA were
not adversely affected by the presence of Myr. Overall,
it may be concluded that even normal (~ 1 mol eq.)
FFA levels modulate the Zn2+-binding capacity of
HSA, but that pathologic levels (up to 5 mol eq. [31–
36]) severely affect or nearly abolish high-affinity Zn2+
binding. It is likely that the physiologically pertinent
longer-chain fatty acids (C16 and C18), owing to their
higher affinity for HSA [40], have an at least similar if
not more pronounced effect.
With the Zn2+-binding constant data for HRG and for
HSA in the presence and absence of FFA in hand, it was
possible to explore whether an increase in plasma FFA
levels is likely to lead to Zn2+ redistribution from HSA
to HRG. All KITC values were corrected for competition
with Tris [29], but, as all experiments were carried out at
physiologic pH and ionic strength, the resulting condi-
tional constants (Table 1) are otherwise valid for the con-
ditions in plasma. Using these constants, we modeled
Zn2+ speciation in the HRG–HSA–FFA system on the
basis of typical physiologic concentrations of exchange-
able Zn2+ (15 lM), HSA (620 lM), and HRG (1 or
2 lM). The effect of FFA was determined as a reduction
in the availability of site A, with the numbers for N1
determined above. Weaker binding to the secondary sites
on HSA was also taken into account, with various combi-
nations of N2 and K2 derived from the fits (Table S2).
All calculated speciation values are reported in Table S3,
and the most salient findings are shown in Fig. 6. As the
availability of site A decreased (Fig. 6A), some Zn2+
became unbound, some Zn2+ became bound by the sec-
ondary site(s) on albumin, and a significant proportion
became bound to HRG (Fig. 6B). At the highest Myr
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Fig. 5. Isothermal titration calorimetry data showing the interaction
between human serum albumin (HSA) and Zn2+ in the presence of
0 mol eq. (○), 1 mol eq. (●), 2 mol eq. ( ), 3 mol eq. (▼) and
5 mol eq. (★) of myristate (Myr). HSA (50 lM) was incubated with
the desired amount of Myr for 2 h at 37 °C. The HSA sample was
then titrated with 5-lL injections of a 1.5 mM ZnCl2 solution (55
injections). The total Zn2+ concentration at the end of the experi-
ment was 246 lM. Experiments were conducted in buffer containing
50 mM Tris and 140 mM NaCl (pH 7.4). For clarity, only the first
halves of the curves are shown (see Fig. S3 for full dataset). The fits
correspond to a ‘two-sets-of-sites’ model with the stoichiometric fac-
tor for the secondary binding site fixed at 1.00. Raw data are shown
in Figs. S9–S14.
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level, HRG had ~ 1.25 mol eq. of Zn2+ bound, as com-
pared with ~ 0.15–0.25 mol eq. at physiologically normal
FFA levels (1–2 mol eq.). According to the ELISA assay
data shown in Fig. 4, an equimolar amount of Zn2+ is
sufficient to significantly increase the affinity of HRG for
unfractionated heparin. It needs to be emphasized that
our estimates are deliberately conservative, and that a
reduction in site A availability to 0.07 still corresponds to
~ 40 lM – in principle, still more than enough to bind all
exchangeable Zn2+. Nevertheless, the binding constants
and concentrations of HSA and HRG seem to be so
finely balanced that even partial obliteration of site A on
HSA leads to a notable shift of Zn2+ from HSA to
HRG. The formation of up to 0.9 lM ‘free Zn2+’ is also
interesting (Fig. S4); it is possible that this fraction
becomes more available for interaction with other plasma
proteins and/or for cellular uptake via ZIP transporters
by endothelial or other cells. Significantly, a reduction in
total plasma Zn2+ is also a hallmark of several disease
states that are characterized by high plasma FFA levels
[52–56].
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Fig. 6. Speciation modeling analysis of plasma Zn2+. (A) Occupation of human serum albumin (HSA) site A in the presence of 0–5 mol. eq.
myristate. (B) Proportion of Zn2+ bound to HRG in the presence of 0–5 mol. eq. myristate. Values for the stoichiometric factor for site A
were extracted from several fits (Table S2) and averaged. For the determination of HRG loading with Zn2+ the conditional constants from
Table 1 were used to model the distribution of Zn2+ (15 lM) in the presence of HSA (620 lM) and HRG (1 or 2 lM). Full speciation data are
reported in Table S3. Errors correspond in each case to 1r. (C) Reaction scheme showing the proposed effects that elevated FFA levels would
have in relation to modulation of HRG–heparin interactions and destabilization of the thrombin-antithrombin III (ATIII) complex. Myr, myri-
state.
Table 1 Conditional Zn2+ binding constants for human serum albu-
min (HSA) and histidine-rich glycoprotein (HRG)
Protein Fixed parameter KITC K
0
HRG – (8.06  0.40) 9 104 1.63 9 105
HSA (site A) – (1.35  0.20) 9 105 2.73 9 105
HSA
[secondary
site(s)]
N2 = 1 (6.1  1.5) 9 103 1.2 9 104
N2 = 2 (7.0  2.7) 9 103 1.4 9 104
The final conditional constants K0 valid for pH 7.4 and physiologic
ionic strength were derived from the KITC constants by correcting
for competition with 50 mM Tris [29]. KITC for site A was derived
from fitting the data in the absence of myristate (Myr) to a sequen-
tial binding sites model with two sites (Table S1). In the case of the
secondary site(s) on HSA, the averages from fitting data in the pres-
ence and absence of Myr are reported
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Speciation modeling of plasma Zn2+ based on the pre-
sented data suggests that elevated FFA levels (as
observed in certain pathologic conditions) will modulate
HRG–heparin interactions, which could potentially
impact on coagulation (Fig. 6C). Our model only consid-
ered serum albumin and HRG, and did not take into
account other Zn2+-binding molecules present in the cir-
culation that could bind at least some of the Zn2+ dis-
placed from albumin. However, the abundance of HRG
in plasma (micromolar levels) and its affinity for Zn2+
suggest that it would probably bind a significant propor-
tion of displaced Zn2+. Furthermore, both ITC (qualita-
tively) and ELISA assay data (quantitatively) indicated
that only a small proportion of the Zn2+ displaced from
serum albumin (1–2 lM) is required to have a pronounced
effect on the affinity of HRG for heparin.
In addition to heparin neutralization, HRG binds with
high affinity to plasminogen in a Zn2+-dependent manner
[57]. Despite this, the effects of this interaction on plas-
minogen conversion to plasmin or its fibrinolytic activity
remain unknown. Moreover, HRG is known to interact
with fibrinogen and compete with thrombin binding on
the c-chain of the protein [58]. This interaction is also
Zn2+-dependent, and its effects on fibrin clot formation
or structure have not been studied. This means that hy-
peractivation of HRG in disease states may also influence
hemostatic functioning through other mechanisms. Zn2+
is also known to influence thrombosis and hemostasis
through interaction with other proteins. For example,
Zn2+ may promote platelet aggregation by enhancing the
interactions of fibrinogen with its cognate receptor, aIIbb3
[59], and of high molecular weight kininogen and FXII
with platelet glycoprotein Ib [60], at the platelet surface.
Thus, the full impact of FFA-mediated displacement of
Zn2+ from HSA on hemostasis may not be limited to the
modulation of HRG–heparin interactions.
The results of the current study are therefore compel-
ling, and provide evidence to suggest that Zn2+-depen-
dent formation of HRG–heparin complexes, following
FFA binding to serum albumin, constitutes a novel
molecular mechanism for the development of hemostatic
complications in individuals with high plasma FFA levels.
Thus, maintenance and monitoring of plasma FFA levels
may prove useful in preventing thrombosis and the for-
mation of obstructive clots.
Addendum
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